Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The role of the Grb2–p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis
Shaosong Zhang, Carla Weinheimer, Michael Courtois, Attila Kovacs, Cindy E. Zhang, Alec M. Cheng, Yibin Wang, Anthony J. Muslin
Shaosong Zhang, Carla Weinheimer, Michael Courtois, Attila Kovacs, Cindy E. Zhang, Alec M. Cheng, Yibin Wang, Anthony J. Muslin
View: Text | PDF
Article Cardiology

The role of the Grb2–p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis

  • Text
  • PDF
Abstract

Cardiac hypertrophy is a common response to pressure overload and is associated with increased mortality. Mechanical stress in the heart can result in the integrin-mediated activation of focal adhesion kinase and the subsequent recruitment of the Grb2 adapter molecule. Grb2, in turn, can activate MAPK cascades via an interaction with the Ras guanine nucleotide exchange factor SOS and with other signaling intermediates. We analyzed the role of the Grb2 adapter protein and p38 MAPK in cardiac hypertrophy. Mice with haploinsufficiency of the Grb2 gene (Grb2+/– mice) appear normal at birth but have defective T cell signaling. In response to pressure overload, cardiac p38 MAPK and JNK activation was inhibited and cardiac hypertrophy and fibrosis was blocked in Grb2+/– mice. Next, transgenic mice with cardiac-specific expression of dominant negative forms of p38α (DN-p38α) and p38β (DN-p38β) MAPK were examined. DN-p38α and DN-p38β mice developed cardiac hypertrophy but were resistant to cardiac fibrosis in response to pressure overload. These results establish that Grb2 action is essential for cardiac hypertrophy and fibrosis in response to pressure overload, and that different signaling pathways downstream of Grb2 regulate fibrosis, fetal gene induction, and cardiomyocyte growth.

Authors

Shaosong Zhang, Carla Weinheimer, Michael Courtois, Attila Kovacs, Cindy E. Zhang, Alec M. Cheng, Yibin Wang, Anthony J. Muslin

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Biochemical characterization of Grb2 and MAPK in murine cardiac tissue 7...
Biochemical characterization of Grb2 and MAPK in murine cardiac tissue 7 days after TAC or sham operation. (a) Load-induced formation of a Grb2-FAK complex. Anti-FAK immunoprecipitates (IP) derived from ventricular lysates were separated by SDS-PAGE and analyzed by immunoblotting with an anti-Grb2 antibody (lower panel). Anti-FAK immunoprecipitates were also analyzed in parallel by immunoblotting with an anti-FAK antibody (upper panel). (b) Reduced Grb2 protein content in Grb2+/– cardiac tissue. Upper panel, ventricular lysates were analyzed by immunoblotting with an anti-Grb2 antibody. Lower panel, quantification of Grb2 protein levels by densitometric analysis of immunoreactive bands. (c) Analysis of p38 MAPK activation in Grb2+/– cardiac tissue. Ventricular lysates were analyzed by immunoblotting with an anti-phospho–p38 MAPK antibody (upper panel). Lysates were also analyzed in parallel by immunoblotting with an anti–p38 MAPK (lower panel) antibody to control for protein content. (d) Analysis of JNK activation in Grb2+/– cardiac tissue. Lysates were analyzed by immunoblotting with an anti–phospho-JNK antibody (upper panel). Lysates were also analyzed in parallel by immunoblotting with an anti-JNK (lower panel) antibody to control for protein content. (e) Analysis of ERK activity in Grb2+/– cardiac tissue. Anti-ERK immunoprecipitates derived from ventricular lysates were analyzed by in vitro kinase assay by use of Elk-1 protein as a substrate. Anti-phospho–Elk-1 antibody immunoblotting was performed to assess ERK activity (upper panel). Lysates were also analyzed in parallel by immunoblotting with an anti-ERK (lower panel) antibody to control for protein content. Sham, sham operation.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts